Genscript Biotech Corporation 1548

Demand for biologics, targeted therapies and personalized medicine is rising, while AI-led protein design and scalable bioprocessing unlock new opportunities.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global recombinant proteins market was valued at US$3.3 billion in 2024 and is projected to reach US$5.8 billion by 2030, expanding at a compound annual growth rate of 10.2%. Ma

Capitalize on gene therapy and vaccine demand through automated, scalable DNA synthesis and actionable segment, regional, and competitive insights.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "DNA Manufacturing Market Size, Share & Trends Analysis Report by Type, Grade, Application, End Use, Region, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering. The global DNA manufacturing market was valued at an estimated USD 6.4 billion in 2025 and is projected to reach US

DNA Synthesis Market Accelerates on Precision Medicine, Synthetic Biology and High-Throughput Automation DemandDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "DNA Synthesis Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global DNA Synthesis Market to Reach USD 11.5 Billion by 2035, Driven by Synthetic Biology and Precision Medicine The global DNA synthesis market, valued at USD 2.5 billion in 2025, is projecte

ProBio, a leading global contract development and manufacturing organization (CDMO) focused on biologics and cell and gene therapies (CGT), today announced a strategic collaboration with Kun Tuo, an IQVIA company and leading clinical research organization (CRO) in China. The partnership aims to accelerate Investigator-Initiated Trials (IITs) and streamline clinical operations for global biopharmaceutical companies seeking to advance innovative therapies in China.

GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while adjusted net profit rose 203.3% to approximately US$62.5 million. The results reflect strong growth across its core businesses, improved operating efficiency, and accelerating demand for AI-enabled drug discovery services.

AI-driven drug discovery demand fuels record growth, with LSG operating profit doubling and full-year guidance raised to 25-30%.

Artificial intelligence can now generate thousands of potential drug molecules in the time it once took to design one, dramatically expanding what scientists can imagine. Yet deciding which designs merit further investment still depends on experimental proof.

Recent price moves and business snapshot Genscript Biotech (SEHK:1548) has seen the stock slip about 0.5% on the day and roughly 5.6% over the past week, while posting a gain of around 13% over the past 3 months. At a last close of HK$12.92, the company carries a market value of about HK$28.3b. It reported revenue of HK$959.526m and a net loss of HK$532.83m across its diversified life sciences and biologics services operations. See our latest analysis for Genscript Biotech. The recent...

DNA synthesis technologies, supported by automated synthesizers, high-throughput platforms, oligonucleotide production systems, gene assembly tools, and AI-driven design software, allow researchers to create precise and custom DNA sequences for a wide range of applications. Leading providers such as Thermo Fisher Scientific Inc., Twist Bioscience, and GenScript Biotech Corporation are continuously enhancing synthesis accuracy, scalability, and turnaround time through technological innovation.

GenScript Biotech Corporation today announced its 2025 Environmental, Social, and Governance (ESG) Report, positioning the company at the forefront of responsible innovation in biotechnology and reinforcing its role as a trusted global partner powering the future of healthcare, science, and sustainability.

GenScript Biotech Corporation, the world's leading provider of CMOS-based DNA synthesis technologies, and Mimulus Corp, the pioneer in Molecular Archive Technology™, today announced a strategic collaboration to industrialize DNA-based data storage, a technology poised to transform how the world preserves data in the age of Artificial Intelligence.

Genscript Biotech Corp (GNNSF) reports a 61.4% revenue surge to $959.5 million, driven by strategic global expansion and key partnerships.